Athanasios Zomas

机构：Takeda (Switzerland), Takeda (Japan)

发表论文 97 篇 · 总被引 2168 次 · h-index 24

代表论文

• Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial (2024 · The Lancet · 被引 140)
• Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma (2016 · Haematologica · 被引 89)
• Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies (2017 · European Journal Of Haematology · 被引 49)
• Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma (2020 · Annals of Hematology · 被引 41)
• No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years (2011 · American Journal of Hematology · 被引 40)
• The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients’ renal function (2011 · Annals of Oncology · 被引 32)